Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China

INTRODUCTION: To investigate the effect of dose maintenance, reduction, or discontinuation of the etanercept biosimilar Yisaipu (YSP) on early axial spondyloarthritis (axSpA) patients in remission with YSP 50 mg once weekly (QW). MATERIAL AND METHODS: Patients were enrolled in three groups: full dos...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Arch Med Sci
Glavni autori: Li, Kun-Peng, Jin, Jing-Yu, Yang, Jin-Shui, Li, Yan, Zhao, Wei, Luo, Gui, Zhu, Jian, Zhang, Jiang-Lin, Huang, Feng
Format: Artigo
Jezik:Inglês
Izdano: Termedia Publishing House 2018
Teme:
Clinical Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6524190/
https://ncbi.nlm.nih.gov/pubmed/31110537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/aoms.2018.76141
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items